NCT00086203 2015-03-25
Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)
FDA Office of Orphan Products Development
Phase 2 Completed
FDA Office of Orphan Products Development
FDA Office of Orphan Products Development
VA Office of Research and Development
Kansas City Veteran Affairs Medical Center